The bill sets forth a mechanism for identifying biotechnology entities that could potentially jeopardize national security due to their affiliations with foreign adversaries. Such companies may include those engaged in joint research or providing data to unsanctioned foreign governments. This legislation represents a significant shift in how biotechnology procurement will be handled at the federal level, placing increased scrutiny on vendors and impacting existing contracts and future acquisitions of biotechnology resources.
Summary
SB3411, known as the Safeguarding American Genetic Data Act of 2023, aims to prohibit the federal government from contracting with certain biotechnology companies deemed to pose a risk to national security. The legislation mandates the establishment of a Federal entity to create guidelines that prevent Executive agencies from acquiring biotechnology services or equipment from companies identified as concerning. This entity will include various high-ranking officials such as the Director of the Office of Management and Budget, the Secretary of Defense, and heads of other relevant departments.
Contention
The discussions surrounding SB3411 highlight concerns over data privacy and the ethical implications of restricting access to biotechnology services that may be vital for advancement in medical research and healthcare. Proponents argue that the bill is necessary for protecting sensitive genetic data and preventing espionage from foreign governments. However, opponents raise questions about the breadth of the definitions involved, particularly regarding which entities are classified as 'companies of concern', which could inadvertently stifle innovation and collaboration in the field of biotechnology.
To direct the Chairman of the Joint Chiefs of Staff to conduct a feasibility study on incorporating militarily-relevant applications of emerging biotechnology into wargaming exercises, and for other purposes.